• Antipyrine B1886 for Reproducible Cell Assays

  2026-08-12

  Learn how Antipyrine (SKU B1886) can support controlled compound handling, viability controls, and BBB permeability workflows. This scenario-based guide connects product specifications with quantitative evidence from a 2025 LLC-PK1-MDR1 barrier-model study.

• Cell Divisions Refine Drosophila Tissue Boundaries

  2026-08-12

  Castle and colleagues show that cell division has a context-dependent role at the Drosophila mesectoderm-ectoderm boundary: divisions can challenge boundary integrity when actomyosin tension is absent, yet also sharpen the interface by increasing ectodermal fluidity. Combining mathematical modelling, division perturbation, laser ablation, quantitative imaging, and cell tracking, the study identifies cellular rearrangement as an additional mechanism of boundary refinement.

• Drug Response Assays: Insights from Schwartz's Dissertation

  2026-08-11

  Hannah Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is an assay-interpretation framework that separates growth inhibition from cell killing while accounting for their different proportions and timing, improving the design of drug-response studies.

• Primidone: From Mysoline to RIPK1 Biomarker Research

  2026-08-11

  Primidone, also known as Mysoline, is more than an established antiepileptic and anti-essential tremor drug. This article connects its TRPM3 and RIPK1 activities with biomarker-led ALS research, assay design, dosing logic, and translational limitations.

• Tacalcitol Monohydrate: Applied Research Workflows

  2026-08-10

  Build reproducible VDR-centered workflows for NGF induction, keratinocyte biology, and colorectal cancer research with Tacalcitol monohydrate. This guide connects dose-response design, 5-fluorouracil combination testing, metabolomics validation, and practical troubleshooting without overstating evidence across disease areas.

• RG7388: Assay Design for p53 Reactivation

  2026-08-09

  RG7388 is a selective MDM2 antagonist for dissecting p53 pathway activation, cancer cell apoptosis induction, and treatment sensitization. This article presents an assay-design framework that separates target engagement from p53 competence and MDM1-associated chemoradiotherapy response.

• JNJ-10198409: PDGF Receptor Inhibitor Research

  2026-08-08

  JNJ-10198409 is a platelet-derived growth factor receptor inhibitor that targets the ATP-binding site of the PDGF-BB receptor. Its reported 4.2 nM IC50 in human coronary artery smooth muscle cells supports research into PDGF-driven proliferation, angiogenesis, tumor biology, and fibrotic disorder mechanisms.

• ATP Precision for p21 mRNA-LNP Translation

  2026-08-07

  Localized p21 mRNA-LNP therapy illustrates how transient gene replacement can be aligned with bladder cancer biology and clinical delivery. This thought-leadership guide connects that translational strategy to the assay architecture behind it, showing how high-purity ATP supports transcription, phosphorylation, kinase, and ligation workflows while emphasizing comparability, controls, and preclinical limitations.

• Applied Workflows for Cucurbitacin I (JSI-124) in STAT3 Rese

  2026-08-07

  Cucurbitacin I (JSI-124) empowers researchers to dissect STAT3-mediated cancer biology with high specificity, offering robust inhibition of tumor growth and cell invasion. This article delivers advanced experimental protocols, troubleshooting strategies, and cross-domain insights, highlighting how APExBIO's Cucurbitacin I streamlines both in vitro and in vivo oncology studies.

• Clozapine N-oxide: Precision Chemogenetic Control in Neurosc

  2026-08-06

  Clozapine N-oxide (CNO) enables non-invasive, reversible modulation of neuronal circuits with unmatched specificity, empowering experiments that dissect brain function at high spatiotemporal resolution. With robust support for DREADDs-based workflows and proven utility in encoding injury signals, CNO from APExBIO is the benchmark for assay rigor in advanced GPCR and neuroimmune research.

• KN-62: Redefining CaMKII Inhibition in Translational Researc

  2026-08-06

  Explore how KN-62, a potent and selective CaMKII inhibitor, is unlocking new possibilities for translational researchers. This article blends deep mechanistic insights with actionable guidance, contrasting KN-62’s specificity with classic calcium channel modulators, and provides protocol parameters for robust experimental results. We connect these findings to metabolism, secretion, and cell cycle regulation, while highlighting APExBIO’s leadership in research-grade inhibitors.

• AMPK–SQSTM1 Feedback Loop Drives Dual Antioxidant Defense in

  2026-08-05

  This study elucidates a double-positive feedback loop between AMPK and SQSTM1/p62 in response to metabolic stress, leading to coordinated activation of both AMPK and NFE2L2/NRF2 antioxidant pathways. The findings clarify adaptive mechanisms in tumor cells and highlight actionable molecular targets for future cancer research.

• SNS-032 (BMS-387032): Deep Mechanistic Insights and Cross-Do

  2026-08-05

  Explore how SNS-032 (BMS-387032), a potent CDK2/7/9 inhibitor, enables advanced research in cancer biology and viral host-pathogen interactions. Uncover new mechanistic insights and protocol guidance beyond conventional applications.

• WZ4003: Applied NUAK1/2 Inhibitor for Cell Migration & Tau A

  2026-08-04

  WZ4003 empowers researchers with nanomolar-selective NUAK1/2 inhibition, enabling robust, reproducible assays for cell migration, proliferation, and tau phosphorylation. Its dual oncology and neurodegeneration relevance, highlighted by recent human brain tissue data, positions WZ4003 as a cornerstone tool for translational research.

• Torin2: Redefining mTOR Inhibition Precision in Cancer Resea

  2026-08-04

  Discover how Torin2, a next-generation mTOR inhibitor, elevates precision in cancer research by enabling advanced analysis of cellular responses. This article provides a unique, protocol-driven perspective on optimizing Torin2 assays and interpreting viability data for translational impact.

7968 records 3/532 page Previous Next 12345 下5页 Last page